Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with <em>P.... (Publications)
this Phase I/IIa double-blind controlled trial was to test the efficacy of the sporozoite-based malaria vaccine PfCS 282-383 (PfCS102) to protect against Plasmodium falciparum parasitaemia. 16 volunteers [...] antibodies against PfCS102 versus none control. 8/8 vaccinees and 6/6 controls challenged developed malaria parasitaemia. The duration from infection to onset of patent parasitaemia was similar in both groups
Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea (Publications)
A Phase I safety and immunogenicity study with a three-component blood- stage malaria vaccine was conducted in adult male subjects living in an endemic area of Papua New Guinea. The preparations were
Habitat-based larval interventions: a new perspective for malaria control (Publications)
environmental management of mosquito larval habitats has been rekindled due to deterioration of malaria in tropical Africa. Environmental management programs were typically implemented as "all-out" campaigns [...] tiveness, and sustainability of such approaches, particularly when implemented along with other malaria control measures
Malaria vaccines: from the laboratory to the field (Publications)
cure of malaria patients with passive transfer of specific immunoglobulins, and iii) protection conferred by vaccination with sporozoites attenuated by radiation, justifies the search for a malaria vaccine [...] include recombinant proteins, synthetic peptides and DNA vaccines, the relevant genes encoding malaria antigens being inserted into a plasmid or a live vector such as vaccinia or poxvirus. A number of [...] Combination B) had an efficacy of 62% in reducing parasite density in Papua New...
